Data / New clinical trials / Company sponsors / Guangdong Raynovent Biotech Co., Ltd
Guangdong Raynovent Biotech Co., Ltd trials: 36 (2026)
Source: ClinicalTrials.gov API v2 (U.S. National Library of Medicine).
ClinicalTrials.gov lists 36 trials with Guangdong Raynovent Biotech Co., Ltd as lead sponsor, 6 of them recruiting or not yet recruiting.
The full list. Clinical trials led by Guangdong Raynovent Biotech Co., Ltd: 36 rows for $5, every trial on ClinicalTrials.gov.
$10 of credit on sign-up, no card. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.
For agents and scripts: this list is ordered at https://specstream.ai/data/clinical-trials/company/guangdong-raynovent-biotech-co-ltd, and every list with its row count and price is at https://specstream.ai/data/lists.json.
The request: Every clinical trial Guangdong Raynovent Biotech Co., Ltd leads on ClinicalTrials.gov, with phase, status, conditions and sites, and each new one.
SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.
- Trials
- 36
- Recruiting or not yet
- 6
- Read on
- November 19, 2026
Trials
The 25 newest of 36, each linked to its ClinicalTrials.gov record. The full list holds every one.
| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
|---|---|---|---|---|---|---|---|---|
| September 18, 2026 | NCT07827027 | Evaluation of the Bioequivalence of RAY1225 Injection in Healthy Participants | Guangdong Raynovent Biotech Co., Ltd | Phase 1 | Not yet recruiting | Basic Science | 68 | clinicaltrials.gov |
| March 10, 2026 | NCT07460284 | A Mass Balance Study Of 14C-RAY1225 Injection In Healthy Chinese Participants | Guangdong Raynovent Biotech Co., Ltd | Phase 1 | Not yet recruiting | Basic Science | 8 | clinicaltrials.gov |
| January 23, 2026 | NCT07362030 | Drug-durg Interaction of RAY1225 With Warfarin, Atorvastatin, Metformin and Digoxin | Guangdong Raynovent Biotech Co., Ltd | Phase 1 | Active not recruiting | Obesity | 32 | clinicaltrials.gov |
| November 17, 2025 | NCT07229820 | Efficacy and Safety of ZSP1273 in Adolecent 12-17 Years Old With Influenza A | Guangdong Raynovent Biotech Co., Ltd | Phase 3 | Completed | Influenza A | 157 | clinicaltrials.gov |
| November 17, 2025 | NCT07229807 | Efficacy and Safety of ZSP1273 in Children 2-11 Years Old With Influenza A | Guangdong Raynovent Biotech Co., Ltd | Phase 3 | Completed | Influenza a | 120 | clinicaltrials.gov |
| August 24, 2025 | NCT07139548 | A Study of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Participants With Type 2 Diabetes | Guangdong Raynovent Biotech Co., Ltd | Phase 3 | Not yet recruiting | T2DM | 600 | clinicaltrials.gov |
| August 24, 2025 | NCT07139535 | A Study of RAY1225 in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone | Guangdong Raynovent Biotech Co., Ltd | Phase 3 | Not yet recruiting | T2DM | 350 | clinicaltrials.gov |
| March 25, 2025 | NCT06893016 | Evaluation of RAY1225 in Adult Participants Who Have Obesity or Are Overweight | Guangdong Raynovent Biotech Co., Ltd | Phase 3 | Recruiting | Obesity | 640 | clinicaltrials.gov |
| October 24, 2024 | NCT06656026 | Pharmacokinetics,Safety and Efficacy of ZSP1273 in Children 2-17 Years Old With Influenza A | Guangdong Raynovent Biotech Co., Ltd | Phase 2 | Completed | Influenza a | 72 | clinicaltrials.gov |
| September 26, 2024 | NCT06613763 | A Study of RAY1225 in Participants With Impaired Kidney Function | Guangdong Raynovent Biotech Co., Ltd | Phase 1 | Completed | Kidney Impairment | 32 | clinicaltrials.gov |
| August 29, 2024 | NCT06577428 | A Study of RAY1225 at Different Injection Sites in Participants With Different Body Sizes | Guangdong Raynovent Biotech Co., Ltd | Phase 1 | Completed | Healthy | 48 | clinicaltrials.gov |
| August 29, 2024 | NCT06577415 | A Study of RAY1225 in Participants With Impaired Liver Function | Guangdong Raynovent Biotech Co., Ltd | Phase 1 | Unknown | Hepatic Impairment | 24 | clinicaltrials.gov |
| April 12, 2024 | NCT06362460 | Mass Balance Study of [14C]RAY1216 in Healthy Adult Male Subjects in China | Guangdong Raynovent Biotech Co., Ltd | Phase 1 | Completed | Pharmacokinetics | 6 | clinicaltrials.gov |
| February 12, 2024 | NCT06254274 | A Study of RAY1225 in Participants With Type 2 Diabetes | Guangdong Raynovent Biotech Co., Ltd | Phase 2 | Completed | T2DM (Type 2 Diabetes Mellitus) | 210 | clinicaltrials.gov |
| February 12, 2024 | NCT06254261 | A Study of RAY1225 in Participants With Obesity | Guangdong Raynovent Biotech Co., Ltd | Phase 2 | Recruiting | Obesity | 270 | clinicaltrials.gov |
| February 8, 2024 | NCT06248567 | Pharmacokinetics of ZSP1273 in Participants With Severe Kidney Disease | Guangdong Raynovent Biotech Co., Ltd | Phase 1 | Completed | Kidney Impairment | 16 | clinicaltrials.gov |
| December 13, 2023 | NCT06169085 | Pharmacokinetics of Leritrelvir(Ray1216) in Elder Participants | Guangdong Raynovent Biotech Co., Ltd | Phase 1 | Completed | Elder | 32 | clinicaltrials.gov |
| December 11, 2023 | NCT06164431 | Bioavailability Study in Healthy Participants, 200mg Tablets ZSP1273 Versus 200mg Granules ZSP1273 | Guangdong Raynovent Biotech Co., Ltd | Phase 1 | Completed | Bioequivalence | 32 | clinicaltrials.gov |
| December 7, 2023 | NCT06161259 | Pharmacokinetics of Leritrelvir(RAY1216) in Participants With Hepatic Impairment | Guangdong Raynovent Biotech Co., Ltd | Phase 1 | Completed | Hepatic Impairment | 24 | clinicaltrials.gov |
| December 7, 2023 | NCT06160622 | Pharmacokinetics of Leritrelvir(RAY1216) in Participants With Severe Kidney Disease | Guangdong Raynovent Biotech Co., Ltd | Phase 1 | Completed | Kidney Impairment | 16 | clinicaltrials.gov |
| December 5, 2023 | NCT06157450 | Pharmacokinetics of ZSP1273 in Elder Participants | Guangdong Raynovent Biotech Co., Ltd | Phase 1 | Completed | Elder | 32 | clinicaltrials.gov |
| September 11, 2023 | NCT06031454 | Drug-durg Interaction of Leritrelvir(RAY1216) With Midazolam, Omeprazole, Rosuvastatin, Verapamil, and Rifampin | Guangdong Raynovent Biotech Co., Ltd | Phase 1 | Completed | Drug Drug Interaction | 56 | clinicaltrials.gov |
| July 20, 2023 | NCT05954624 | Drug-durg Interaction of ZSP1273 With Digoxin, Rosuvastatin,Itraconazole and Probenecid | Guangdong Raynovent Biotech Co., Ltd | Phase 1 | Completed | Drug Drug Interaction | 49 | clinicaltrials.gov |
| July 12, 2023 | NCT05942365 | A Drug Interaction Study Assess the Effects of ZSP1273 Tablets on the Pharmacokinetics of Warfarin and Midazolam | Guangdong Raynovent Biotech Co., Ltd | Phase 1 | Completed | Drug Drug Interaction, Warfarin, Midazolam | 28 | clinicaltrials.gov |
| May 24, 2023 | NCT05873426 | Mass Balance Study of [14C]ZSP1273 in Healthy Adult Male Subjects in China | Guangdong Raynovent Biotech Co., Ltd | Phase 1 | Completed | Pharmacokinetics | 6 | clinicaltrials.gov |
By phase
| Phase | Trials |
|---|---|
| Phase 1 | 22 |
| Phase 1/2 | 2 |
| Phase 2 | 5 |
| Phase 3 | 7 |
By status
| Status | Trials |
|---|---|
| Completed | 27 |
| Not yet recruiting | 4 |
| Recruiting | 2 |
| Active not recruiting | 2 |
| Unknown | 1 |
Conditions
| Condition group | Trials |
|---|---|
| Obesity | 4 |
| Non-alcoholic Fatty Liver Disease | 3 |
| Renal Insufficiency | 3 |
| Idiopathic Pulmonary Fibrosis | 1 |
| COVID-19 | 1 |
| Diabetes Mellitus, Type 2 | 1 |
Where the register publishes
U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown. Free to quote with credit and a link. Copying in bulk needs a data licence. Spot a wrong value? Write to [email protected] with the link to this page.
$10 of credit on sign-up, no card.
Business lists in the United States
- Orthopedic surgery practices in the United States
- Paralegal companies in the United States
- Pediatric oncology practices in the United States
- Plasterers in the United States
- Powder coating companies in the United States
- Promotional products companies in the United States